| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8623761 | Seminars in Arthritis and Rheumatism | 2018 | 25 Pages |
Abstract
Infliximab therapy for patients with refractory PM and DM was well tolerated and may benefit a subset of patients.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Adam MD, Megha MD, Christine DO, Angelina MD, Galen MD, Joseph PT, Imelda Victoria MD, Sara MD MPH, Michael O. DSc, PT, Paul H. MD, Frederick W. MD, PhD, Mark MD,